ASH 2022: Short-course Brentuximab Vedotin with Chemotherapy is Highly Active in Early-Stage Bulky Hodgkin LymphomaASH 2022
ASH 2022: Short-course Brentuximab Vedotin with Chemotherapy is Highly Active in Early-Stage Bulky Hodgkin LymphomaASH…
News
Where Are They Now? Deborah Stephens, DO
Where Are They Now? Deborah Stephens, DO When did you become interested in the study…
A Multi-Layered View to Lymphoma Research
A Multi-Layered View to Lymphoma Research Some people are born to be scientists, and Eric…
The U.S. Food and Drug Administration Approves Pirtobrutinib (Jaypirca) for Relapsed/Refractory Mantle Cell Lymphoma
On January 27, 2023 the U.S. Food and Drug Administration (FDA) announced it has approved pirtobrutinib…
The U.S. Food and Drug Administration Approves Zanubrutinib (Brukinsa) for Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL)
On January 19, the U.S. Food and Drug Administration (FDA) announced it has approved bruton tyrosine…
The U.S. Food and Drug Administration Approves Mosunetuzumab-axgb (Lunsumio) for Follicular Lymphoma
On December 22, 2022, the U.S. Food and Drug Administration (FDA) announced it has approved…
In Remembrance: Errol M. Cook
December 23, 2022 – It is with great sadness that the Lymphoma Research Foundation (LRF)…
Transforming Loss into Hope for Adolescents and Young Adults with Lymphoma
No parent should ever have to go through the excruciating experience of losing a child.…
Read the Latest Issue of Pulse: Fall 2022
Read the Fall 2022 edition of Pulse.
A Caregiver that Keeps on Giving
Roy Bridges has the type of life story you need to read to believe. Starting…
Stay informed with news, alerts and other resources.
